// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Real life EP lab without fluoroscopy

L Ayala Valani - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

AMPK-ACC signaling modulates platelet phospholipids content and potentiate platelet function and thrombus formation

S Lepropre - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study

D Brieger - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Factors associated with troponin elevation and risk of cardiac events in patients with heart failure and preserved ejection fraction

P Myhre - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Clinical outcomes, mortality, and causes of death in patients with NSTEMI according to heart failure at admission: insights from a large contemporary revascularization trial

B Popovic - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

eptifibatide

Reduction in heart failure admission rate after transcatheter edge-to-edge tricuspid valve repair for severe tricuspid regurgitation

E Ho - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Predicting risk at the point of care: NT-proBNP improves performance of the LACE index among patients hospitalized for Heart Failure (HF)

H G C Van Spall - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Vulnerable plaques are revealed by fractional flow reserve but not by instantaneous wave-free ratio

R S Driessen - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Adenosine

Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?

F H Verbrugge - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The prognostic importance of myocardial fibrosis detected by late-gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) in new-presentation dilated cardiomyopathy (DCM)

K Sree Raman - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Long-term prognostic value of non-invasive fractional flow reserve derived from coronary CT angiography (FFRct)

A R Ihdayhid - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

New electrocardiographic risk score for the prediction of ventricular fibrillation in Brugada type 1 ECG pattern

A Deliniere - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics

M V Huisman - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Pradax

Benzodiazepine-free cardiac anesthesia for reduction of delirium (B-Free): a two-centre pilot study to determine the feasibility of a multi-centre, randomized, cluster crossover trial

J Spence - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prognostic impact and major determinants of physical activity level in a real-life SCAD population: insights from the CLARIFY registry

S Biscaglia - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Risk stratification of patients with apparently idiopathic premature ventricular contractions: data from a multicenter international cardiac magnetic resonance registry

G Nucifora - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Predictive value of a biomarker panel for coronary plaque morphology in patients with stable coronary artery disease

M J Bom - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial

A Kalayci - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

betrixaban

Relationship between structural brain damage and cognitive function in patients with atrial fibrillation

S Aeschbacher - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry

V Schirripa - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved